Xspray Pharma
25.00 SEK
+3.95 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+3.95 %
-7.24 %
-1.88 %
-18.26 %
-28.88 %
-15.71 %
-36.81 %
-70.61 %
-14.88 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.19B SEK
Turnover
6.05M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.8
2026
Interim report Q2'26
5.11
2026
Interim report Q3'26
11.2
2027
Annual report '26
All
Press releases
3rd party
ShowingAll content types
New number of shares and votes in Xspray Pharma after new share issue April 2026
Interim Report First Quarter 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools